Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.

What is AOD-9604?

AOD-9604 is a synthetic peptide based on the C-terminal “lipolytic domain” of human growth hormone — the small region thought to be responsible for growth hormone’s fat-related effects, without the full hormone’s actions on growth and blood sugar (Ng et al., 2000).

What the preclinical research examined

In obese Zucker rats, daily oral AOD-9604 over 19 days reduced body-weight gain by more than 50% versus controls and increased lipolytic activity in adipose tissue — and, unlike intact growth hormone, did not impair insulin sensitivity in glucose-clamp testing (Ng et al., 2000). In obese mice, AOD-9604 reduced body weight and fat and raised expression of the β3-adrenergic receptor, a key lipolytic receptor in fat cells; a knockout study indicated its fat-burning actions are not mediated directly through that receptor (Heffernan et al., 2001).

How it is thought to work

The research framing is that AOD-9604 may stimulate fat breakdown (lipolysis) and fat oxidation while sparing the glucose-related effects of full growth hormone — a profile of interest in metabolic research (Ng et al., 2000; Heffernan et al., 2001).

The limits of the current evidence

  • The supportive efficacy data are overwhelmingly from rodent models; robust human evidence of weight-loss benefit has not been established, and AOD-9604 is not an approved drug in the United States.
  • Promising animal results frequently do not translate to humans; this material is supplied for laboratory research use only.

References

According to PubMed:

  1. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. doi:10.1159/000053183
  2. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knock-out mice. Endocrinology. 2001. doi:10.1210/endo.142.12.8522
Disclaimer: This content is provided for educational and informational purposes only and reflects published research. It is not medical advice and makes no claim regarding the diagnosis, treatment, cure, or prevention of any disease. Products referenced are intended solely for in-vitro laboratory research use only (RUO); they are not for human or veterinary use, consumption, or application. Where a compound is approved by a regulatory authority, that approval applies only to specific medical indications under professional supervision and not to the research material sold here.

Related Posts